文献速递消化系统肿瘤

PRODIGY:新辅助DOS化疗联合手术及辅助S-1对比单纯手术及辅助S-1治疗可切除晚期胃癌的III期研究

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
PubMed 文献 · J Clin Oncol · 2021-06-16

PRODIGY是一项III期随机对照研究,在韩国可切除局部晚期胃癌患者中比较新辅助多西他赛+奥沙利铂+S-1(DOS)后手术及辅助S-1(CSC组)与单纯手术及辅助S-1(SC组)的疗效。

要点

  • 新辅助DOS方案可显著改善可切除局部晚期胃癌患者的PFS。
  • 新辅助治疗期间发生2例5级不良事件(发热性中性粒细胞减少和呼吸困难)。

核心结论

  • 在韩国可切除局部晚期胃癌患者中,新辅助DOS化疗作为围手术期化疗的一部分有效且可耐受。

研究设计与样本

  • III期随机对照研究(PRODIGY,NCT01515748),在18个韩国研究中心纳入20-75岁、ECOG PS 0-1、组织学确诊胃或胃食管结合部腺癌(cTNM:T2-3N+或T4Nany)的患者。

主要发现

  • 敏感性分析(意向性分析和界标PFS分析)证实了上述结果。
  • 治疗耐受良好;新辅助治疗期间发生2例5级不良事件(发热性中性粒细胞减少和呼吸困难)。

关键数值与推荐

  • CSC组方案:新辅助DOS(多西他赛50 mg/m2、奥沙利铂100 mg/m2静脉第1天,S-1 40 mg/m2口服每日两次第1-14天,每3周重复,共3周期),随后D2手术,术后辅助S-1。
  • SC组方案:D2手术后辅助S-1(40-60 mg口服每日两次,第1-28天,每6周重复,共8周期)。

临床怎么用

  • 对于韩国可切除局部晚期胃癌患者,可考虑新辅助DOS化疗联合手术及辅助S-1的围手术期治疗模式。
  • 新辅助DOS方案耐受性良好,但需关注发热性中性粒细胞减少等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative chemotherapy in European phase III studies, the phase III PRODIGY study (ClinicalTrials.gov identifier: NCT01515748) investigated whether neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 could improve outcomes versus standard treatment in Korean patients with resectable LAGC. PATIENTS AND METHODS: Patients 20-75 years of age, with Eastern Cooperative Oncology Group performance status 0-1, and with histologically confirmed primary gastric or gastroesophageal junction adenocarcinoma (clinical TNM staging: T2-3N+ or T4Nany) were randomly assigned to D2 surgery followed by adjuvant S-1 (40-60 mg orally twice a day, days 1-28 every 6 weeks for eight cycles; SC group) or neoadjuvant DOS (docetaxel 50 mg/m2, oxaliplatin 100 mg/m2 intravenously day 1, S-1 40 mg/m2 orally twice a day, days 1-14 every 3 weeks for three cycles) before D2 surgery, followed by adjuvant S-1 (CSC group). The primary objective was progression-free survival (PFS) with CSC versus SC. Two sensitivity analyses were performed: intent-to-treat and landmark PFS analysis. RESULTS: Between January 18, 2012, and January 2, 2017, 266 patients were randomly assigned to CSC and 264 to SC at 18 Korean study sites; 238 and 246 patients, respectively, were treated (full analysis set). Follow-up was ongoing in 176 patients at data cutoff (January 21, 2019; median follow-up 38.6 months [interquartile range, 23.5-62.1]). CSC improved PFS versus SC (adjusted hazard ratio, 0.70; 95% CI, 0.52 to 0.95; stratified log-rank P = .023). Sensitivity analyses confirmed these findings. Treatments were well tolerated. Two grade 5 adverse events (febrile neutropenia and dyspnea) occurred during neoadjuvant treatment. CONCLUSION: PRODIGY showed that neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, is effective and tolerable in Korean patients with LAGC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kang YK, Yook JH, Park YK, et al. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021. PMID: 34133211. doi:10.1200/JCO.20.02914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。